Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeffrey Gruskay

Neonatal-Perinatal Medicine Milford, CT Medical Doctor

NPI 1588674345 CMS profile 298362

50 Commerce Park, Milford, CT 06460

Open in the dashboard

General payments

$3,535

210 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jeffrey Gruskay of Milford, CT is reported in the CMS Open Payments database as having received $3,535 across 210 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Neonatal-Perinatal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $491 24
2024 General $578 29
2023 General $486 25
2022 General $543 34
2021 General $494 31
2020 General $469 32
2019 General $475 35

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffrey Gruskay
  • Neonatal-Perinatal Medicine median
  • Middle half of Neonatal-Perinatal Medicine
  • National median

In program year 2025, general payments to Jeffrey Gruskay were reported at $491. Among 879 Neonatal-Perinatal Medicine profiles paid that year, the median was $77 and the middle half received between $26 and $145.

Show as a table
Year Jeffrey Gruskay Neonatal-Perinatal Medicine median Middle half National median
2019 $475 $70 $22–$125 $163
2020 $469 $39 $18–$108 $114
2021 $494 $49 $18–$122 $132
2022 $543 $47 $21–$149 $149
2023 $486 $49 $23–$140 $160
2024 $578 $65 $24–$132 $164
2025 $491 $77 $26–$145 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Tris Pharma Inc $642 57 payments
  2. Merck Sharp & Dohme Corporation $390 21 payments
  3. Cranial Technologies, Inc $281 18 payments
  4. Sanofi Pasteur Inc. $246 10 payments
  5. GlaxoSmithKline, LLC. $235 11 payments
  6. Corium, Inc. $222 12 payments
  7. Pfizer Inc. $196 11 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $183 11 payments
  9. kaleo, Inc. $167 9 payments
  10. Supernus Pharmaceuticals, Inc. $111 6 payments
  11. Other $860 44 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,535 210 payments
Products named General payments · program years 2019–2025
  1. GARDASIL 9 $343 18 payments
  2. Doc Band $281 18 payments
  3. Dyanavel XR $263 24 payments
  4. VAXNEUVANCE $259 13 payments
  5. VAXELIS $222 12 payments
  6. Azstarys $222 12 payments
  7. BEXSERO $218 10 payments
  8. Quillivant XR $208 21 payments
  9. BEYFORTUS $186 7 payments
  10. VYVANSE $148 8 payments
  11. Other $2,879 154 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

210 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neonatal-Perinatal Medicine in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record